Physician profile
John Steen
NPI 1952162984
$3,686.11
in general payments reported to CMS, 2019-2025
24 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,567 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $15.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,670.53 |
| Education | $15.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.66 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.46 | 2024-2025 | Xifaxan, Trulance, Relistor |
| Phathom Pharmaceuticals, INC. | $342.77 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $335.17 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $313.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $299.19 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $234.54 | 2024-2025 | |
| Gilead Sciences, INC. | $169.26 | 2024-2025 | |
| Enterra Medical, INC. | $161.76 | 2024 | |
| Qol Medical, LLC | $138.24 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $132.27 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $80.62 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $64.26 | 2024-2025 | Uplizna |
| Pfizer INC. | $64.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $54.69 | 2024-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $47.66 | 2025 | |
| Intercept Pharmaceuticals, INC. | $44.38 | 2024-2025 | |
| Daiichi Sankyo INC. | $43.12 | 2024-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $33.93 | 2025 | Vowst |
| Lilly USA, LLC | $32.14 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2025 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $16.98 | 2024 | Monoferric |
| Boston Scientific Corporation | $15.02 | 2024 | Watchman Flx |
| Organon LLC | $11.72 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.